Overview

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Status:
Recruiting
Trial end date:
2024-02-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Axitinib
Lenvatinib